Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin http://finance.yahoo.com/news/cellceutix-announces-positive-top-line-155109970.html